Successful combination treatment of a patient with progressive juvenile localized scleroderma (morphea) using imatinib, corticosteroids, and methotrexate

Pediatric Dermatology

Volumn 30, Issue 6, 2013, Pages

  Inamo, Yasuji ^a   Ochiai, Toyoko ^b  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SURUGADAI NIHON UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; METHOTREXATE; PREDNISOLONE; RHEUMATOID FACTOR;

ANKLE; ARTICLE; CASE REPORT; CELL PROLIFERATION; CHILD; CORTICOSTEROID THERAPY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FIBROBLAST; FINGER JOINT; FINGER MALFORMATION; FOREARM; HAND; HEART DISEASE; HISTOPATHOLOGY; HUMAN; IMMUNOTHERAPY; JAPANESE; KIDNEY DISEASE; KNEE; LEUKOCYTE COUNT; LIVER DISEASE; MORPHEA; POLYARTHRITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROXIMAL INTERPHALANGEAL JOINT; RANGE OF MOTION; SKINFOLD THICKNESS; SYSTEMIC THERAPY; THROMBOCYTE;

ADRENAL CORTEX HORMONES; BENZAMIDES; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HAND DERMATOSES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SCLERODERMA, LOCALIZED; TREATMENT OUTCOME;

EID: 84887625241     PISSN: 07368046     EISSN: 15251470     Source Type: Journal    
DOI: 10.1111/j.1525-1470.2012.01882.x     Document Type: Article

References (11)

1. Zulian F, Vallongo C, Woo P, et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum 2005; 52: 2873-2881.
2. Zulian F, Martini G, Vallongo C, et al. Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2011; 63: 1998-2006.
3. Torok KS, Arkachaisri T,. Methotrexate and corticosteroids in the treatment of localized scleroderma: a standardized prospective longitudinal single-center study. J Rheumatol 2012; 39: 286-294.
4. Distler JH, Jungel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56: 311-322.
5. Bibi Y, Gottlieb AB,. A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis. J Am Acad Dermatol 2008; 59: 654-658.
6. Laxer RM, Zulian F,. Localized scleroderma. Curr Opin Rheumatol 2006; 18: 606-613.
7. Peterson LS, Nelson AM, Su WP,. Classification of morphea (localized scleroderma). Mayo Clin Proc 1995; 70: 1068-1076.
8. Arkachaisri T, Vilaiyuk S, Torok KS, et al. Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study. Rheumatology (Oxford) 2010; 49: 373-381.
9. Arkachaisri T, Vilaiyuk S, Li S, et al. The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures. J Rheumatol 2009; 36: 2819-2829.
10. Sfikakis PP, Gorgoulis VG, Katsiari CG, et al. Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) 2008; 47: 735-737.
11. Moinzadeh P, Krieg T, Hunzelmann N,. Imatinib treatment of generalized localized scleroderma (morphea). J Am Acad Dermatol 2010; 63: e102-e104.